References
- Commonwealth of Australia. Guidelines for the pharmaceutical industry in preparation of submissions to the Pharmaceutical Benefits Advisory Committee: including submissions involving economic analysis. Woden (ACT) Department of Health, Housing and Community Services. 1990
- Ontario Ministry of Health. Guidelines for preparation of economic analysis to be included in submission to the Drug Programs Branch for listing in the Ontario Drug Benefit Formulary/ Comparative Drug Index. Ministry of Health, Toronto 1991
- Kanis J A, Johnell O, Gullberg B, et al. Evidence for efficiency of drugs affecting bone metabolism in preventing hip fracture. BMJ 1992; 305: 1124–8
- Jönsson B, Hedbrant J, Johnell O. A computer simulation model to analyse the cost effectiveness of fracture prevention of osteoporosis. Technical description [Working paper]. The Economic Research Institute, Stockholm School of Economics, StockholmSweden 1993
- Gärdsell, et al. Predicting various fragility fractures in women by forearm bone densitometry: a follow up study. Calcif Tissue Int 1993; 52: 348–53
- Data on file. Center for Clinical and Basic Research, BallerupDenmark
- Browner W S, Seelet D G, Vogt T M, Cummings S R. Nontraumatic mortality in elderly women with low bone mineral density. Lancet 1991; 338: 335–58
- Sernbo I. Hip fracture. dissertation, Lund University, Department of Orthopaedics, Malmö General Hospital, MalmöSweden 1988
- Keene G S, Parker M J, Pryor G A. Mortality and morbidity after hip fractures. BMJ 1993; 307: 1248–50
- Hillner B E, Hollenberg J P, Pauker S G. Postmenopausal estrogens in prevention of osteoporosis: benefit virtually without risk of cardiovascular effects are considered. Am J Med 1986; 80: 1115–7
- Borgquist L, Lindelböw G, Thorngren K-G. Cost of hip fracture: rehabilitation of 180 patients in primary health care. Acta Orthop Scand 1991; 62: 39–48
- Kind P, Rosser R, Williams A. Valuation of quality of life: some psychometric evidence. The value of life and safety, M W Jones-Lee. North-Holland, Amsterdam 1982
- Gudex C, et al. Comparing scaling methods for health state valuations: Rosser revisited, [discussion paper 107]. University of York, Centre for Health Economics, New YorkEngland 1993
- Johnell O, Sernbo I. Consequences of hip fracture: a prospective study over 1 year. Osteoporosis Int 1993; 3: 148–53
- Edebalk P G, Lindgren B, Persson U, Svensson M. Offentliga sjukhem och enskilda vardhem: patienter, vardassistenter och omsorgskostnader. 1993; 4, IHE Arbetsrapport
- Johannesson M, Borgquist L, Jönsson B. The costs of treating hypertension in Sweden. Scand J Primary Health Care 1991; 9: 155–60
- Fass. 1993, Lakemedelsinformation 1993
- SBU. Hyperloni. 1994, Report from the Swedish Council on Technology Assessment in Health Care
- Tostesson A NA. A review and update of cost-effectiveness of hormone replacement therapy in the menopause. Medical-economic aspects of hormone replacement therapy, J-M Cossery. Parthenon Publishing Group. 1993
- Overgaard K, Hasen M A, Jensen S B, Christiansen C. Effects of Salcatonia given intranasally on bone mass and fracture rates in established osteoporosis: a dose response study. BMJ 1992; 305: 556–61
- Consensus Development Conference: Diagnosis, Prophylaxis and Treatment of Osteoporosis. Am J M 1993; 94: 646–50